EAM
ZNTL icon

Erste Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Erste Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,800
Closed -$36.8K – 575
2024
Q3 		$36.8K Hold
9,800
– – ﹤0.01% 516
2024
Q2 		$41.2K Hold
9,800
– – ﹤0.01% 512
2024
Q1 		$149K Hold
9,800
– – ﹤0.01% 481
2023
Q4 		$153K Hold
9,800
– – ﹤0.01% 493
2023
Q3 		$192K Hold
9,800
– – ﹤0.01% 479
2023
Q2 		$276K Hold
9,800
– – ﹤0.01% 466
2023
Q1 		$163K Hold
9,800
– – ﹤0.01% 504
2022
Q4 		$180K Hold
9,800
– – ﹤0.01% 497
2022
Q3 		$211K Hold
9,800
– – ﹤0.01% 493
2022
Q2 		$266K Hold
9,800
– – 0.01% 488
2022
Q1 		$447K Hold
9,800
– – 0.01% 446
2021
Q4 		$818K Hold
9,800
– – 0.01% 379
2021
Q3 		$603K Hold
9,800
– – 0.01% 384
2021
Q2 		$521K Hold
9,800
– – 0.01% 406
2021
Q1 		$395K Hold
9,800
– – 0.01% 404
2020
Q4 		$534K Buy
+9,800
New +$442K 0.01% 380

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Erste Asset Management's ZNTL Position: Q4 2024 in Review

Erste Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 9,800 shares — an estimated $36.8K sold.

Erste Asset Management first reported a position in ZNTL in Q4 2020 and held it in 16 quarters. The position peaked at $818K in Q4 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

  • Erste Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Erste Asset Management sold 9,800 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $36.8K.
  • Erste Asset Management first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 16 quarters.
  • Erste Asset Management's Zentalis Pharmaceuticals position peaked at $818K in Q4 2021.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on Erste Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.